Dayle Sampson is vice president of bioinformatics at Elysium Health where he drives ongoing development of Elysium’s proprietary Algorithmic Platform for Epigenetic Examination (APEX). Dayle specializes in applied machine learning within the context of human health and disease. Previously he was the director of bioinformatics at Immunexpress, Inc. where he developed diagnostic tests to detect infections leading to sepsis. This culminated in two FDA 510(k) de novo clearances of first-in-class assays. Prior to his work with Immunexpress, he consulted for both government and private sectors on information science and applied predictive health monitoring. Dayle also held academic research positions at the Institute of Biomedical Innovation, Queensland University of Technology where he worked on tissue damage and repair in wound healing and human performance.
Dayle is co-inventor on multiple patents and has published in the areas of proteomics, transcriptomics, host response, infections, and human adaptation. Dayle holds a BAppSci (Hons) in biotechnology and forensic science and a Ph.D. in bioinformatics from the Queensland University of Technology, Australia.